Juniper Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 82   

Articles published

JNP 6.79 -0.12 (-1.74%)
price chart
Columbia Laboratories, Inc. to Become Juniper Pharmaceuticals, Inc.
BOSTON, April 2, 2015 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) (the "Company"), today announced that it will adopt Juniper Pharmaceuticals, Inc. as its new corporate brand. The name change will become effective Friday, April 10, 2015, ...
Analysts Expect Juniper Pharmaceuticals Inc (NASDAQ:JNP) to Announce ($0.08 ...
Juniper Pharmaceuticals logo Shares of Juniper Pharmaceuticals Inc (NASDAQ:JNP) have been assigned an average broker rating score of 1.00 (Strong Buy) from the three brokers that cover the stock, Zacks Investment Research reports.
Juniper Pharmaceuticals Inc (NASDAQ:JNP) 4Q Loss Widens
Juniper Pharmaceuticals Inc (NASDAQ:JNP) reported its financial results for the fourth quarter that showed a wider net loss and missed Wall Street analysts' estimations.
Juniper Pharmaceuticals Reports Fourth Quarter and Full-Year 2015 Financial ...  PR Newswire (press release)
Juniper Pharmaceuticals' (JNP) CEO Frank Condella on Q4 2015 Results ...  Seeking Alpha
Juniper Pharmaceuticals Inc (JNP) Rating Lowered to Sell at TheStreet
Juniper Pharmaceuticals logo Juniper Pharmaceuticals Inc (NASDAQ:JNP) was downgraded by analysts at TheStreet from a “hold” rating to a “sell” rating in a research report issued on Monday, Market Beat.
Juniper Pharmaceuticals to Report First Quarter 2016 Results on May 4, 2016
BOSTON, April 26, 2016 /PRNewswire/ -- The management team of women's health therapeutics developer Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), will hold a conference call on May 4, 2016, to discuss financial results of ...
Zacks Investment Research Lowers Juniper Pharmaceuticals Inc (JNP) to Sell
Juniper Pharmaceuticals logo Juniper Pharmaceuticals Inc (NASDAQ:JNP) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Monday, MarketBeat reports.
Juniper Pharmaceuticals Inc (JNP) Downgraded by Zacks Investment Research to ...  MicroCap Magazine
Juniper Pharmaceuticals Inc (JNP) Stock Rating Lowered by Zacks Investment ...
Juniper Pharmaceuticals logo Juniper Pharmaceuticals Inc (NASDAQ:JNP) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday, MarketBeat Ratings reports.
GSA Capital Partners LLP Buys 73500 Shares of Juniper Pharmaceuticals Inc (JNP)
Juniper Pharmaceuticals logo GSA Capital Partners LLP increased its position in Juniper Pharmaceuticals Inc (NASDAQ:JNP) by 73.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission.
Juniper Pharmaceuticals Inc (JNP) Downgraded by Zacks Investment Research to ...
Juniper Pharmaceuticals Inc logo Zacks Investment Research cut shares of Juniper Pharmaceuticals Inc (NASDAQ:JNP) from a hold rating to a sell rating in a research note published on Friday morning, AnalystRatings.
Columbia Laboratories Begins Trading as Juniper Pharmaceuticals (JNP)
BOSTON, April 13, 2015 /PRNewswire/ -- Effective this morning, Columbia Laboratories, Inc. is now Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("the Company"), and its Nottingham, UK based subsidiary Molecular Profiles, Ltd., is now Juniper Pharma ...